Last10K.com

Casi Pharmaceuticals, Inc. (CASI) SEC Filing 8-K Material Event for the period ending Tuesday, October 23, 2018

Casi Pharmaceuticals, Inc.

CIK: 895051 Ticker: CASI

View differences made from one to another to evaluate Casi Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Casi Pharmaceuticals, Inc..

Continue

Assess how Casi Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Casi Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Material Contracts, Statements, Certifications & more

Casi Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Ticker: CASI
CIK: 895051
Form Type: 8-K Corporate News
Accession Number: 0001144204-18-055161
Submitted to the SEC: Wed Oct 24 2018 4:57:46 PM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Tuesday, October 23, 2018
Industry: Biological Products No Disgnostic Substances
Events:
  1. Financial Exhibit
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/casi/0001144204-18-055161.htm